Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7498.074 | 0.9880 | 0.9779 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7498.074 | 0.3972 | -0.1443 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7498.074 | 0.3972 | -0.1443 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7498.074 | 0.0558 | -0.8592 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7498.074 | 0.0558 | -0.8592 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7498.074 | 0.0118 | -0.9663 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7498.074 | 0.0118 | -0.9663 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7498.074 | 0.0039 | -0.9878 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7498.074 | 0.0039 | -0.9878 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7498.074 | 0.0084 | -0.9753 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7498.074 | 0.0084 | -0.9753 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 7498.074 | 0.0062 | -0.9813 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 7498.074 | 0.0062 | -0.9813 | 1.0877 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14841.203 | 0.9573 | 0.9173 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14841.203 | 0.9573 | 0.9173 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14841.203 | 0.9873 | 0.9753 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14841.203 | 0.9873 | 0.9753 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14841.203 | 0.8531 | 0.7148 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14841.203 | 0.8531 | 0.7148 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14841.203 | 0.2345 | -0.5087 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14841.203 | 0.2345 | -0.5087 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14841.203 | 0.0312 | -0.9303 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14841.203 | 0.0312 | -0.9303 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14841.203 | 0.0139 | -0.9682 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14841.203 | 0.0139 | -0.9682 | 1.0330 |